By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere reported after the close of the market Wednesday that its full-year 2010 revenues declined 9 percent to $2 million from $2.2 million.

The Northbrook, Ill.-based molecular diagnostics developer fell short of analysts' consensus estimate of $2.4 million in revenues for the year.

Its product sales increased to $1.4 million from $1.1 million year over year, while its grant and contract revenue fell to $610,000 from $1.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.